ID   SKOV3/VP
AC   CVCL_Y280
DR   cancercelllines; CVCL_Y280
DR   CGH-DB; 9125-4
DR   Wikidata; Q54954774
RX   PubMed=7911742;
RX   PubMed=14973057;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0532 ! SK-OV-3
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 05-10-23; Version: 17
//
RX   PubMed=7911742; DOI=10.1007/BF00685075;
RA   Kubota N., Nishio K., Takeda Y., Ohmori T., Funayama Y., Ogasawara H.,
RA   Ohira T., Kunikane H., Terashima Y., Saijo N.;
RT   "Characterization of an etoposide-resistant human ovarian cancer cell
RT   line.";
RL   Cancer Chemother. Pharmacol. 34:183-190(1994).
//
RX   PubMed=14973057; DOI=10.1158/0008-5472.CAN-3263-2;
RA   Yasui K., Mihara S., Zhao C., Okamoto H., Saito-Ohara F., Tomida A.,
RA   Funato T., Yokomizo A., Naito S., Imoto I., Tsuruo T., Inazawa J.;
RT   "Alteration in copy numbers of genes as a mechanism for acquired drug
RT   resistance.";
RL   Cancer Res. 64:1403-1410(2004).
//